Physician profile
Mark W Minor
NPI 1982609657
$20,819.90
in general payments reported to CMS, 2019-2025
45 companies · $3,031 in 2025
The $3,031 reported for 2025 was more than what 79% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,600 · 2020: $1,123 · 2021: $2,126 · 2022: $3,035 · 2023: $2,492 · 2024: $2,412 · 2025: $3,031.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,723 · Education: $156 · Consulting Fee: $55.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,723.11 |
| Education | $156.42 |
| Consulting Fee | $55.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $5,112.25 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $2,592.95 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Csl Behring | $1,798.91 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Takeda Pharmaceuticals U.S.A., INC. | $1,475.32 | 2020-2025 | Hyqvia, Cuvitru, Takhzyro |
| Pfizer INC. | $1,199.39 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,149.94 | 2019-2025 | Dupixent |
| Genzyme Corporation | $851.41 | 2019-2025 | |
| Glaxosmithkline, LLC. | $835.16 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Abbvie INC. | $561.27 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $491.56 | 2019-2023 | Spiriva Respimat |
| Novartis Pharmaceuticals Corporation | $389.48 | 2019-2025 | |
| Pharming Healthcare, INC. | $388.10 | 2019-2024 | Ruconest |
| Biocryst US Sales Co., LLC | $386.26 | 2021-2025 | Orladeyo |
| Grifols USA, LLC | $383.79 | 2019-2025 | Xembify |
| Adma Biomanufacturing LLC | $373.43 | 2022-2025 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $323.22 | 2022-2025 | Ayvakit |
| Ars Pharmaceuticals Operations, INC. | $251.77 | 2025 | Neffy |
| Genentech USA, INC. | $234.98 | 2019-2023 | Xolair |
| Optinose US, INC. | $192.84 | 2019-2025 | |
| Bio Products Laboratory USA, INC. | $184.46 | 2022-2023 | Gammaplex, Coagadex |
| Galderma Laboratories, L.P. | $163.99 | 2024-2025 | Nemluvio |
| Teva Pharmaceuticals USA, INC. | $163.60 | 2020-2022 | |
| Amgen INC. | $136.36 | 2020-2025 | Tezspire |
| Kaleo, INC. | $129.99 | 2019-2024 | Auvi-Q |
| Greer Laboratories, INC. | $123.47 | 2019-2025 | Oralair |
| Sanofi-Aventis U.S. LLC | $117.75 | 2019-2021 | |
| Alk-Abello, INC | $115.82 | 2019-2022 | |
| Regeneron Pharmaceuticals, INC. | $69.53 | 2024 | Dupixent |
| Kedrion Biopharma, INC. | $69.18 | 2024-2025 | Rhogam Ultra-Filtered Plus, Albuked, Kedrab |
| Gc Biopharma USA, INC. | $68.78 | 2024-2025 | Alyglo, Alyglo |
| Ionis Pharmaceuticals, INC. | $60.67 | 2025 | Dawnzera |
| Phadia US INC. | $59.13 | 2021-2024 | Immunocap |
| Leo Pharma INC. | $54.61 | 2022-2023 | Adbry |
| Incyte Corporation | $48.20 | 2021-2025 | Opzelura |
| Insmed, INC. | $47.03 | 2025 | Brinsupri, Arikayce |
| Cycle Pharmaceuticals INC | $36.16 | 2024-2025 | Sajazir |
| Lilly USA, LLC | $29.22 | 2024 | Ebglyss |
| Aimmune Therapeutics, INC. | $28.17 | 2022 | |
| Merck Sharp & Dohme LLC | $20.55 | 2023 | |
| Azurity Pharmaceuticals, INC. | $20.43 | 2025 | Alvesco |
| Sunovion Pharmaceuticals INC. | $18.46 | 2019 | |
| Paratek Pharmaceuticals, INC. | $18.10 | 2025 | Nuzyra |
| Biocryst Pharmaceuticals, INC. | $15.43 | 2020 | |
| Hikma Pharmaceuticals USA | $14.75 | 2023 | Ryaltris |
| Circassia INC. | $14.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Minor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.